BRANDNEWS

BRAND INSTITUTE
Where Great Brands Begin!®

DSI DrugSafetyInstitute
A Subsidiary of BRAND INSTITUTE, inc.
Where Safe Names Begin!

Brand Institute is proud to have partnered with 900+ healthcare companies on over 3,200 pharmaceutical brand names, highlighted by these most recent name approvals from ANVISA

PLEASE BE SAFE AND THANK YOU FOR MAKING
BRAND INSTITUTE THE WORLD'S #1 NAMING COMPANY!

November 6, 2020	October 26, 2020	October 13, 2020
Spravato® (esketamine) CIII nasal spray JANSSEN	RYBELSUS® semaglutide tablets 7mg | 14mg NOVO NORDISK	Evrysdi™ risdiplam 60 mg powder for oral solution ROCHE
October 10, 2020	**September 21, 2020**	**September 9, 2020**
Erelzi® (etanercept-szzs) SANDOZ	Symtuza® darunavir/cobicistat/emtricitabine/ tenofovir alafenamide tablets 800mg/150mg/200mg/10mg JANSSEN	Idacio® adalimumab JANSSEN
August 8, 2020	**July 20, 2020**	**May 5, 2020**
LUMOXITI® moxetumomab pasudotox-tdfk for injection ASTRAZENECA	GIVLAARI® (givosiran) injection for subcutaneous use 189 mg/mL ALNYLAM	Lonsurf® (trifluridine and tipiracil) tablets TAIHO
May 4, 2020	**April 6, 2020**	**February 26, 2020**
INJECTION Ruxience™ rituximab-pvvr PFIZER	REXULTI® brexpiprazole tablets LUNDBECK	Influenza Vaccine FLUCELVAX® QUADRIVALENT SEQIRUS

DRUG SAFETY INSTITUTE (DSI) NAMING & LABELING EXPERT SPOTLIGHT

Todd Darwin Bridges, R. Ph.

Global President
Drug Safety Institute

Mr. Bridges joined DSI – Rockville in May 2018 as Global President. Prior to joining DSI, Mr. Bridges was the Director of the Division of Medication Error Prevention and Analysis (DMEPA) in the Office of Surveillance and Epidemiology at the U.S. Food and Drug Administration (FDA). He has more than thirteen years of DMEPA experience with three of those years as the Director of DMEPA.

As Director of DMEPA, Mr. Bridges was responsible for supervising the premarket review and approval of proposed proprietary/brand drug names, labels/labeling, packaging, product design, United States Adopted Names, biological product proper name suffixes, and human factors studies in order to reduce the potential for medication errors with products regulated by the Center for Drug Evaluation and Research (CDER). DMEPA conducts review and analysis of post-marketing medication errors submitted to CDER to determine if regulatory action such as label/labeling revisions, names change, product redesign, or post-marketing communications to stakeholders is needed. DMEPA also works with external stakeholders, regulators, and researchers to better understand the causes of medication errors and the effectiveness of interventions at preventing them, and provides guidance to the pharmaceutical industry on drug development considerations from a medication errors perspective.

Mr. Bridges has contributed to FDA policy and guidances related to medication errors, represented FDA as a member of the National Coordinating Council for Medication Error Reporting and Prevention as well as the Joint Commission's Patient Safety Advisory Group, and was responsible for establishing FDA's ongoing membership with the International Medication Safety Network. In addition to his FDA experience, Mr. Bridges has thirteen years of pharmacy practice and supervisory experience prior to joining FDA. He has also received specialty training in medication error prevention and analysis from the Institute for Safe Medication Practices.

Mr. Bridges earned a B.S. in Pharmacy from Virginia Commonwealth University's Medical College.



Domenica Redeschi, R.Ph.

Director, Brazil & Latin America Regulatory Affairs
Drug Safety Institute

Dr. Redeschi joined BI - Miami as a Drug Safety Evaluator in 2015 and was promoted to Coordinator, South American Division in 2018. Prior to joining BI, she was in retail pharmacy with CVS for ten years. She graduated from UMC Pharmacy School in São Paulo, Brazil in 2000, and became a registered pharmacist in the United States in 2009. In 2012, she received her Consulting Pharmacist license and, in early 2018, she became certified in Brazilian Regulatory Affairs. In April 2019, Ms. Redeschi was a speaker at the OTC Seminar promoted by Anvisa and ABIMIP and in October of that year she was a speaker at the Naming Development Seminar promoted by Anvisa and Sindusfarma.

Dr. Redeschi has led the regulatory and safety research efforts for dozens of Brazilian and Latin American projects, highlighted by recent ANVISA approvals that include GSK's Trelegy, EMS' Bexai, Seqirus' Flucelvax, and Daiichi-Sankyo's Lixiana.B.Sc. from the Centro Universitário São Camilo..

BRAND INSTITUTE'S 2019 GLOBAL SHARE OF MARKET NAME APPROVALS



Corporate Headquarters
200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL	BOSTON	CHICAGO	DALLAS	FRANKFURT	LONDON	LOS ANGELES	MIAMI	NEW YORK
+41 78-879-4619	(781) 602-6044	(312) 475-9600	(512) 369-9100	+49 6196-400-966	+44 207-240-2200	(310) 830-6111	(305) 984-6889	(212) 557-2100

OTTAWA	RALEIGH-DURHAM	ROCKVILLE	SAN FRANCISCO	SÃO PAULO	SEATTLE	SEOUL	TOKYO	TORONTO
(613) 482-1333	(919) 572-9311	(301) 984-1055	(415) 421-3200	+55 11 945-364-083	(206) 204-5111	+82 6433-9555	+81(03) 6861-7517	(416) 622-5777